These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 30314913

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.
    Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
    Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, Schulze K, Hillemanns P, Suryakiran P, Thomas F, Struyf F.
    Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
    [Abstract] [Full Text] [Related]

  • 6. Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M, Unger ER.
    Hum Vaccin Immunother; 2019; 15(7-8):1980-1985. PubMed ID: 31017850
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine.
    Klein NP, Wiesner A, Bautista O, Group T, Kanu K, Li ZL, McCauley J, Saxena K, Tota J, Luxembourg A, Bonawitz R.
    Pediatrics; 2024 Aug 01; 154(2):. PubMed ID: 38978512
    [Abstract] [Full Text] [Related]

  • 8. Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials.
    Sauvageau C, Panicker G, Unger ER, De Serres G, Schiller J, Ouakki M, Gilca V.
    Hum Vaccin Immunother; 2020 Mar 03; 16(3):590-594. PubMed ID: 31545130
    [Abstract] [Full Text] [Related]

  • 9. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
    Guevara A, Cabello R, Woelber L, Moreira ED, Joura E, Reich O, Shields C, Ellison MC, Joshi A, Luxembourg A.
    Vaccine; 2017 Sep 05; 35(37):5050-5057. PubMed ID: 28789851
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM, Canh DG, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NT, Tsu V, LaMontagne DS.
    JAMA; 2011 Apr 13; 305(14):1424-31. PubMed ID: 21486975
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
    Wu T, Hu YM, Li J, Chu K, Huang SJ, Zhao H, Wang ZZ, Yang CL, Jiang HM, Wang YJ, Lin ZJ, Pan HR, Sheng W, Wei FX, Li SW, Wang Y, Zhu FC, Li CG, Zhang J, Xia NS.
    Vaccine; 2015 Jul 31; 33(32):3940-6. PubMed ID: 26100924
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M.
    Hum Vaccin Immunother; 2015 Jul 31; 11(3):732-8. PubMed ID: 25714044
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of the 9-valent HPV vaccine in men.
    Castellsagué X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R, Luxembourg A, Kaplan SS.
    Vaccine; 2015 Nov 27; 33(48):6892-901. PubMed ID: 26144901
    [Abstract] [Full Text] [Related]

  • 15. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
    Lin L, Macias Parra M, Sierra VY, Salas Cespedes A, Granados MA, Luque A, Karkada N, Castrejon Alba MM, Romano-Mazzotti L, Borys D, Struyf F.
    Pediatr Infect Dis J; 2019 Oct 27; 38(10):1061-1067. PubMed ID: 31469776
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
    Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, Takeuchi Y, Cheung TH, Kim SC, Huang LM, Kim BG, Kim YT, Kim KH, Song YS, Lalwani S, Kang JH, Sakamoto M, Ryu HS, Bhatla N, Yoshikawa H, Ellison MC, Han SR, Moeller E, Murata S, Ritter M, Sawata M, Shields C, Walia A, Perez G, Luxembourg A.
    J Infect Dis; 2018 Jun 05; 218(1):95-108. PubMed ID: 29767739
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
    Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajden M, Ouakki M, Murphy D, Trevisan A, Dionne M.
    Hum Vaccin Immunother; 2014 Jun 05; 10(8):2438-45. PubMed ID: 25424952
    [Abstract] [Full Text] [Related]

  • 18. A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.
    Zeng Y, Moscicki AB, Sahasrabuddhe VV, Garcia F, Woo H, Hsu CH, Szabo E, Dimond E, Vanzzini S, Mondragon A, Butler V, DeRose H, Chow HS.
    BMC Cancer; 2019 Apr 01; 19(1):290. PubMed ID: 30935375
    [Abstract] [Full Text] [Related]

  • 19. Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.
    Lazcano-Ponce E, Torres-Ibarra L, Cruz-Valdez A, Salmerón J, Barrientos-Gutiérrez T, Prado-Galbarro J, Stanley M, Muñoz N, Herrero R, Hernández-Ávila M.
    J Infect Dis; 2019 Jan 01; 219(1):41-49. PubMed ID: 30085139
    [Abstract] [Full Text] [Related]

  • 20. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
    Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, Penny ME, Restrepo JA, Romaguera J, Maansson R, Moeller E, Ritter M, Chen J.
    Hum Vaccin Immunother; 2015 Jan 01; 11(6):1313-22. PubMed ID: 25912208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.